论文部分内容阅读
目的 探讨持续气道正压通气( CPAP)治疗2 型糖尿病合并阻塞性睡眠呼吸暂停低通气综合征( OSAHS)患者对其炎症因子水平及预后的影响.方法 回顾性分析2015 年1 月~2016 年1 月本院诊治的60 例2 型糖尿病合并OSAHS患者临床资料, 随机分为两组, 对照组患者29 例采用常规治疗,研究组患者31 例在常规治疗的基础上采用 CPAP 治疗.对比两组血糖相关指标、炎症因子水平及预后情况.结果 治疗后, 两组空腹血糖( FBG) 、空腹胰岛素( FINS) 、血清果糖胺( FMN) 、胰岛素抵抗指数(HOMA-IR)水平均下降, 但是研究组各项指标水平下降幅度更显著( P <0. 01) ; 研究组呼吸暂停低通气指数(AHI)与最低血氧饱和度(L-SaO2)指标改善幅度大于对照组(P<0. 01); 两组肿瘤坏死因子(TNF-α)和白介素-6 (IL-6)水平均有明显下降, 研究组尤其明显, 比较差异有统计学意义(P <0. 01) .进一步发现TNF-α、 IL-6 水平与FMN、 HOMA-IR、 AHI呈正相关, 与L-SaO2呈负相关.结论 2 型糖尿病合并OSAHS患者采用以 CPAP 为主的治疗, 有可能是减轻炎症反应和缓解病情进展的关键, 可有效缓解患者临床症状, 同时能够提高生活质量, 改善预后.“,”Objective To investigate the effect of the nasal continuous positive airway pressure (NCPAP) on inflammatory factors and prognosis in patients with type 2 diabetes mellitus and obstructive sleep apnea-hypopnea syndrome (OSAHS). Methods The clinical data of 60 patients with type 2 diabetes mellitus and OSAHS in our hospital from January 2015 to January 2016 were ret-rospectively analyzed. The patients were divided into the control group and the experimental group according to the treatment. 29 pa-tients in the control group were treated routinely. 31 patients in the experimental group were treated routinely and with CPAP. The levels of blood glucose related indicators and inflammatory factors and prognosis were compared between the two groups. Results Af-ter treatment, the levels of blood glucose related indicators (FBG, FINS, FMN and HOMA-IR) decreased in both groups, but the level of each index was more lower in the experimental group (P<0. 01). The levels of apnea hypopnea index (AHI ) and L-SaO2 in the experimental group were higher than those in the control group (P<0. 01). The levels of TNF-α and IL-6 in both groups were significantly decreased, especially in the experimental group, there were significant differences compared with the control group (P<0. 01). TNF-α and IL-6 levels were positively correlated with FMN, HOMA-IR, AHI and negatively correlated with L-SaO2. Conclusion The CPAP-based treatment may reduce the inflammatory reaction, improve the clinical symptoms and prognosis in patients with type 2 diabetes mellitus and OSAHS.